Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google
ENTITY
SMARTSCORE: 3.4/5
Asymchem Laboratories Tianjin (002821 CH)
Watchlist
79
Analysis
Health Care
•
China
Asymchem Laboratories (Tianjin) Co., Ltd. operates as a pharmaceutical company. The Company researches, produces, and sells organic and inorganic chemicals, medicines, and other related products. Asymchem Laboratories serves customers worldwide.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Innovent Biologics Inc
•
06 Mar 2024 00:55
2024 High Conviction Update: Innovent (1801.HK) - Recent Promising Business Updates and 2024 Outlook
Innovent's product revenue growth will remain strong in 2024.The main flashpoint for performance is after the approval of mazdutide in...
Xinyao (Criss) Wang
Follow
440 Views
Share
bullish
•
Midea Group Co Ltd A
•
25 Oct 2023 00:31
Midea A/H Listing - Early Look - Probably Raising Acquisition Currency
Midea officially filed for an H-share listing yesterday. As per media reports the company is looking to raise up to US$3bn in Hong Kong.
Sumeet Singh
Follow
975 Views
Share
bullish
•
Thematic (Sector/Industry)
•
09 Oct 2023 00:55
China's Weight Loss Drug Market – The Investment Opportunities and the Risks Behind
The GLP-1 target has been recognized as a blockbuster target, which has attracted great enthusiasm from investors.We analyzed related investment...
Xinyao (Criss) Wang
Follow
444 Views
Share
bearish
•
Quantitative Analysis
•
16 Mar 2025 02:00
A-H Premium Weekly (Mar 14th): CIMC, Sinotrans, Joinn Lab, Huahong Semicon, Huaneng Power
We analyzed A-H premium changes in the past week and highlight A-H premium changes for CIMC, Sinotrans, Joinn Lab, Huahong Semicon, Huaneng Power,...
Ke Yan, CFA, FRM
Follow
319 Views
Share
bullish
•
Jiangsu Hengrui Medicine
•
12 Feb 2025 02:44
Jiangsu Hengrui Pharma A/H Listing - Innovation and Overseas Expansion Driving Earnings Rebound
Jiangsu Hengrui Medicine (600276 CH) a China-based pharmaceutical company, aims to raise around US$2bn in its H-share listing.
Sumeet Singh
Follow
384 Views
Share
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.51.2
x